Роль фекальных биомаркеров в прогнозировании воспалительных заболеваний кишечника
Фекальные биомаркеры (ФБМ) отражают выраженность воспаления слизистой оболочки кишечника в большей степени по сравнению с аналогичными маркерами сыворотки крови. Сывороточные маркеры могут изменяться по многим причинам, однако местное воспаление в кишечнике не всегда соответствует системному воспалительному ответу, выявленному в крови. На сегодня идентифицировано много ФБМ, но лишь некоторые из них были тщательно изучены у детей. В данной статье более подробно рассмотрены следующие перспективные маркеры: кальпротектин, S100A12, M2-пируваткиназа, остеопротегерин, миелопероксидазы, HMGB 1, матриксные металлопротеиназы, а также рекомендуемый в настоящее время фекальный кальпротектин. В настоящий момент не существует единого универсального маркера, который обладал бы высокой чувствительностью, специфичностью и прогностической способностью как при болезни Крона (БК), так и при язвенном колите (ЯК).Камалова А.А., Гарина Г.А., Ханафина М.А., Валеева И.Х
Ключевые слова
воспалительные заболевания кишечника
фекальные биомаркеры
Список литературы
1. De Souza, Fiocchi C., Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739–49. Doi: 10.1038/nrgastro.
2. Schechte A., Griffiths C., Gana J.C., et al. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut. 2015;64:580–88. Doi: 10.1136/gutjnl-2014-306999.
3. Turner D., Griffiths A.M., Veerman G., et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460–65. Doi: 10.1016/j.cgh.2013.04.049.
4. Oliva S., Thomson M., de Ridder L., et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the Espghan. J Pediatr Gastroenterol Nutr. 2018;67:414–30. Doi: 10.1097/MPG.0000000000002092.
5. Roseth A., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017–20.
6. Pang T., Leach S.T., Katz T., et al. Fecal biomarkers of intestinal health and disease in children. Front Pediatr. 2018;67:414–30. Doi: 10.3389/fped.2014.00006.
7. Sherwood R.A. Faecal markers of gastrointestinal inflammation. J Clin Pathol. 2012;65:981–85. Doi: 10.1136/jclinpath-2012-200901.
8. Langhorst J., Elsenbruch S., Koelzer J., et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–69. Doi: 10.1111/j.1572-0241.2007.01556.x.
9. Lopez R.N., Leach S.T., Lemberg D.A., et al. Faecal biomarkers in inflammatory bowel disease. Am J Gastroenterol Hepatol. 2016;32:577–82. Doi: 10.1111/jgh.13611.
10. Ruemmele F.M., Veres G., Kolh K.L., et al. European Crohn’s and Colitis Organisation, European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207. Doi: 10.1016/j.crohns.2013.06.001.
11. Turner D., Ruemmele F.M., Orlanski-Meyer T., et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence based Consensus Guideline From the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:292–310. Doi: 10.1097/MPG.0000000000002036.
12. Van Rheenen P.F., Aloi M., Assa A., et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN Guideline Update. J Crohn’s Colitis. 2020;15:171–94. Doi: 10.1093/ecco-jcc/jjaa161.
13. Kolho K., Alfthan H. Concentration of fecal calprotectin in 11,255 children aged 0-18 years. Scand J Gastroenterol. 2020;55:1024–27. Doi: 10.1080/00365521.
14. Koninckx C.R., Donat E., Benninga M.A., et al. The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr. 2021;72:617–40. Doi: 10.1097/MPG.0000000000003046.
15. Walker G.J., Chanchlani N., Thomas A., et al. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child. 2020;105(10):957–63. Doi: 10.1136/archdischild-2019-317823.
16. Ливзан М.А., Долгих Т.И., Лялюкова Е.А. Фекальный кальпротектин в комплексной диагностике заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2013:12:83–6.
17. Day A.S., Ehn M., Gearry R.B., et al. Fecal S100A12 in healthy infants and children. Disease Markers.2013;35:295–99. Doi: 10.1155/2013/873582.
18. Leach S.T., Yang Z., Messina I., et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1321–31. Doi: 10.1080/00365520701416709.
19. Foell D., Wittkowski H., et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2007;216:183–92. Doi: 10.1002/path.2394.
20. Kaiser T., Langhorst J.., Wittkowski H., et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706–13. Doi: 10.1136/gut.2006.113431.
21. Dabritz J., Langhorst J., Lugering A., et al. Improving relapse prediction in inflammatory bowel disease by neutrophilderived S100A12. Inflammatory Bowel Diseases. 2013;19:1130–38. Doi: 10.1097/MIB.0b013e318280b1cd.
22. Kyle B.D., Agbor T.A., Sharif S., et al. Fecal calprotectin, CRP and leucocytes in IBD patients: comparison of biomarkers with biopsy results. J Can Assoc Gastroenterol. 2021;4:84–90. Doi: 10.1093/jcag/gwaa009.
23. De Jong N.S., Leach S.T., Day A.S. Fecal S100A12: a novel noninvasive marker in children with Crohn’s disease. Inflamm Bowel Dis. 2006;12:566–72. Doi: 10.1097/MIB.0b013e318280b1cd.
24. Czub E., Herzig K.H., Szaflarska-Popawska A., et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147–50. Doi: 10.1080/00365520701320513.
25. Judd T.A., Day A.S., Lemberg D.A., et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493–99. Doi: 10.1111/j.1440-1746.
26. Leach S.T., Day A.S., Messenger R., et al. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study. J Pediatr Gastroenterol Nutr 2020;70(5):580–585. doi: 10.1097/MPG.0000000000002615.
27. Chung-Faye G., Hayee B., Maestranzi S., et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374–78. Doi: 10.1002/ibd.20214.
28. Turner D., Leach S.T., Mack D., et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–12. Doi: 10.1136/gut.2010.211755.
29. Beaugerie L., Svrcek M., Seksik P., et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–75. Doi: 10.1053/j.gastro.2013.03.044.
30. Olen O., Erichsen R., Sachs M.C., et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020:5:475–84. Doi: 10.1016/S2468-1253(20)30005-4.
31. Chaparro M., Garre A., Ricart E., et al. Differences between childhood-and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther. 2019;49:419–28. Doi: 10.1111/apt.15114.
32. Olen O., Askling J., Sachs M.C., et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964–2014. BMJ. 2017;358:j3951. Doi: 10.1136/bmj.j3951
33. Hardt P.D., Mazurek S., Toepler M., et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980–84. Doi: 10.1038/sj.bjc.6602033
34. Duvoisin G., Lopez R.N., Day A.S. Novel biomarkers and the future potential of biomarkers in inflammatory bowel disease. Mediators of Inflamm. 2017;2017:1936315. Doi: 10.1155/2017/1936315.
35. Sylvester F.A., Turner D., Draghi A. 2nd et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflammatory Bowel Diseases. 2011;17:1726–30. Doi: 10.1002/ibd.21561.
36. Nahidi L., Leach S.T., Sidler M.A., et al. Osteoprotegerin in pediatric Crohn’s disease and the effects of exclusive enteral nutrition. Inflamm Bowel Dis. 2011;17:516–53. Doi: 10.1002/ibd.21361.
37. Gordon, R.J., Gordon, C.M. Bone Health in Pediatric Patients with IBD: What Is New? Curr Osteoporos Rep. 2021;19:429–35. Doi: 10.1007/s11914-021-00691-x.
38. Peterson C.G., Eklund E., Taha Y., et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–62. Doi: 10.1111/j.1572-0241.
39. Newell K.J., Matrisian L.M., Driman D.K. Matrilysin (matrix metalloproteinase-7) expression in ulcerative colitisrelated tumorigenesis. Molecular Carcinogenesis. 2002;34:59–63. Doi: 10.1002/mc.10049.
40. Coskun M., Bjerrum J.T., Seidelin J.B., et al. MiR-20b, miR-98, miR-125b-1, and let-7e as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19:4289–99. Doi: 10.3748/wjg.v19.i27.4289.
41. Vitali R., Stronati L., Negroni A., et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029–40. Doi: 10.1038/ajg.2011.231.
42. Palone F., Vitali R., Cucchiara S., et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448–57. Doi: 10.1097/MIB.0000000000000113.
43. Medina C., Radomski M.W. Role of matrix metalloproteinases in intestinal inflammation. The Journal of Pharmacology and Experimental Therapeutics. 2006;318:933–38. Doi: 10.1124/jpet.106.103465.
44. von Lampe B., Barthel B., Coupland S.E., et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63–7. Doi: 10.1136/gut.47.1.63.
45. Gao Q., Meijer M.J., Kubben F.J., et al. Expression of matri metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis. 2005;37:584–92. Doi: 10.1016/j.dld.2005.02.011.
46. Farkas K., Sarodi Z., Balint A., et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis. 2015;9:231–37. Doi: 10.1093/ecco-jcc/jjv005.
47. Kolho K.L., Sipponen T., Valtonen E., Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43–50. Doi: 10.1007/s00384-013-1775-9.
48. Maronek M., Marafini I., Gardlik R., et al. Metalloproteinases in Inflammatory Bowel Diseases. J Inflamm Res. 2021;14:1029–41. Doi: 10.2147/JIR.S288280.
Об авторах / Для корреспонденции
Автор для связи: Аэлита Асхатовна Камалова, д.м.н., профессор кафедры госпитальной педиатрии, Казанский государственный медицинский университет, кафедра госпитальной педиатрии, Казань, Россия; aelitakamalova@gmail.com
ORCID:
А.А. Камалова (A.A. Kamalova), https://orcid.org/0000-0002-2957-680X
Г.А. Гарина (G.A. Garina), https://orcid.org/0000-0002-4333-8779
М.А. Ханафина (M.A. Khanafina), https://orcid.org/0009-0009-0814-0773
Также по теме
